There was a significant increase of GFAP protein in patients suffering from secondary progressive MS, whereas patient with a relapsing remitting disease course displayed levels similar to healthy controls (see Table 2 for baseline characteristics of patients and Fig. 3A,B for results). Here, GFAP is linked to myeloid sarcoma.